Ann Arbor, MI, United States of America

Yangbing Li

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 7.8

ph-index = 1


Company Filing History:


Years Active: 2020-2021

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Yangbing Li in Protein Degradation

Introduction

Yangbing Li, based in Ann Arbor, Michigan, is an accomplished inventor known for his significant contributions to the field of biochemistry and medicinal chemistry. With a total of three patents to his name, Li has focused much of his research on developing small molecule compounds that target the MDM2 protein, which plays a critical role in cancer progression.

Latest Patents

Among his notable inventions, Yangbing Li has recently developed compounds represented by Formula I-A that provide a novel approach in the treatment of cancers through the degradation of the MDM2 protein. These compounds, along with their pharmaceutically acceptable salts, hydrates, and solvates, are designed to target conditions or disorders responsive to MDM2 degradation. Furthermore, he also holds patents for additional small molecule MDM2 protein degraders. These compounds, defined in his specifications, are meant to treat not only cancer but other diseases and disorders linked to MDM2 protein dysregulation.

Career Highlights

Yangbing Li is currently affiliated with the University of Michigan, where he collaborates with leading minds in the field. His innovative work in protein degradation has far-reaching implications for therapeutic strategies against various types of cancer, showcasing his commitment to advancing medical science.

Collaborations

Throughout his career, Li has benefited from collaboration with notable colleagues, including Shaomeng Wang and Jiuling Yang. These partnerships have facilitated significant advancements in their shared pursuit of groundbreaking therapies that utilize small molecules to target and degrade problematic proteins associated with cancer.

Conclusion

In summary, Yangbing Li's work is instrumental in the development of new therapeutic options for cancer treatment. His research at the University of Michigan, supported by key collaborations, aims to combat diseases at their molecular foundation, paving the way for innovative solutions in modern medicine. His patents on MDM2 protein degraders are a testament to his innovative spirit and dedication to improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…